Compare compounds

AOD-9604

Vials

2 / 5 mg

Dosing data

Lab reference — not listed

Ipamorelin

Start

0.1 mg

Range

0.1–0.3 mg

Frequency

1–3× daily

Cycle

8–12 weeks

Vials

5 / 10 mg

AOD-9604

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone, developed to study fat metabolism without growth hormone's growth-promoting effects.

Ipamorelin

Ipamorelin is a synthetic pentapeptide that releases growth hormone through the ghrelin (GH secretagogue) receptor, like GHRP-6. It was developed from a GHRP-1 series with the central Ala-Trp dipeptide removed.

AOD-9604

• It was developed by Metabolic Pharmaceuticals as a potential obesity treatment and had reached phase IIa trials by February 2002.
• A 2026 sports-medicine review groups it with unapproved peptides that look favourable in animal models but have scarce rigorous human safety data.

Ipamorelin

• In rat pituitary cells and in anaesthetised rats and conscious swine, GH-release potency and efficacy were similar to GHRP-6.
• In swine it did not change FSH, LH, prolactin or TSH, and unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol across a wide dose range.
• In adult female rats, 15 days of treatment dose-dependently increased longitudinal bone growth (42 to up to 52 µm/day) without changing total IGF-I.

AOD-9604

• Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
• Listed as prohibited in sport by the World Anti-Doping Agency.
• Reviewers warn of potential for serious harm when unapproved peptides are used outside regulatory oversight.

Ipamorelin

• Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
• Listed as prohibited in sport by the World Anti-Doping Agency.
• Published evidence is preclinical; no peer-reviewed controlled human efficacy trial is cited here.

AOD-9604

2 references · view

Ipamorelin

2 references · view